Status:
COMPLETED
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Attention Deficit Disorder With Hyperactivity
Substance-Related Disorders
Eligibility:
All Genders
15-30 years
Phase:
PHASE4
Brief Summary
Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adol...
Detailed Description
High rates of ADHD have been reported in adolescents with SUD. In addition, untreated ADHD is a risk factor for developing SUD. Atomoxetine is a norepinephrine reuptake inhibitor, and is currently use...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of ADHD
- Current or recent (within the three months prior to study entry) SUD, including marijuana and alcohol abuse
- ADHD CGI-S score of greater to or equal to 4
Exclusion
- Any Unstable medical condition
- Recent history of intravenous drug use or cocaine dependence
- Currently abusing ecstasy, cocaine, gamma-hydroxybutyrate, methamphetamine, amphetamine, opioids, phencyclidine, or benzodiazepine
- Mental retardation or organic brain syndrome
- Currently psychotic or history of bipolar disorder
- Currently taking any psychotropic or anti-substance abuse disorder medications
- Current DSM-IV diagnosis of major depression, depressive disorder, or anorexia
- Pregnant or breastfeeding
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2006
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00218322
Start Date
September 1 2004
End Date
April 1 2006
Last Update
November 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114